In the case of CTLA-4 neutralizing antibodies, autoimmunity including colitis, dermatitis, and hepatitis, has occurred13,14, whereas CTLA-4-Ig treatment resulted in a higher incidence of respiratory infections15,16. The gene discussed is CTLA4; the disease is colitis.